Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression

BJU International

Volumn 106, Issue 3, 2010, Pages 418-423

  Brimo, Fadi ^a   Vollmer, Robin T ^b   Friszt, Matthew ^c   Corcos, Jacques ^d   Bismar, Tarek A ^e,f,g  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d Department of Urology ^*  (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

Prognosis; Prostate cancer; Syndecan 1

Indexed keywords

BIOLOGICAL MARKER; SYNDECAN 1;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SYNDECAN-1; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955737582     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09099.x     Document Type: Article

References (28)

1. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000 85 : 60 7
2. Isaacs JT. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol 1997 150 : 1511 1521
3. Zellweger T, Ninck C, Mirlacher M et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003 55 : 20 9
4. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM. Expression profiling using cDNA microarrays. Nat Genet 1999 21 : 10 4
5. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001 412 : 822 826
6. Luo J, Zha S, Gage WR et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002 62 : 2220 2226
7. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003 95 : 661 668
8. Bernfield M, Kokenyesi R, Kato M et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992 8 : 365 393
9. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997 327 : 1 16
10. Barbareschi M, Maisonneuve P, Aldovini D et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003 98 : 474 483
11. Anttonen A, Heikkila P, Kajanti M, Jalkanen M, Joensuu H. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 2001 32 : 297 305
12. Fujiya M, Watari J, Ashida T et al. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 2001 92 : 1074 1081
13. Kambham N, Kong C, Longacre TA, Natkunam Y. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol 2005 13 : 304 310
14. Chen CL, Ou DL. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum Pathol 2006 37 : 1279 1285
15. Shariat SF, Svatek RS, Kabbani W et al. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int 2008 101 : 232 237
16. Epstein JI, Allsbrook WC Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006 13 : 57 9
17. Elenius K, Salmivirta M, Inki P, Mali M, Jalkanen M. Binding of human syndecan to extracellular matrix proteins. J Biol Chem 1990 265 : 17837 17843
18. Sun X, Mosher DF, Rapraeger A. Heparan sulfate-mediated binding of epithelial cell surface proteoglycan to thrombospondin. J Biol Chem 1989 264 : 2885 2889
19. Kiviniemi J, Kallajoki M, Kujala I et al. Altered expression of syndecan-1 in prostate cancer. APMIS 2004 112 : 89 97
20. Anttonen A, Kajanti M, Heikkila P, Jalkanen M, Joensuu H. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 1999 79 : 558 564
21. Ito Y, Yoshida H, Nakano K et al. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 2003 43 : 157 164
22. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997 74 : 482 491
23. Mikami S, Ohashi K, Usui Y et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 2001 92 : 1062 1073
24. Numa F, Hirabayashi K, Kawasaki K et al. Syndecan-1 expression in cancer of the uterine cervix: association with lymph node metastasis. Int J Oncol 2002 20 : 39 43
25. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P, Grenman R. Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol 1997 117 : 312 315
26. Gokden N, Greene GF, Bayer-Garner IB, Spencer HJ, Sanderson RD, Gokden M. Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Appl Immunohistochem Mol Morphol 2006 14 : 173 177
27. Chen D, Adenekan B, Chen L et al. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 2004 63 : 402 407
28. Ragnarsson L, Stromberg T, Wijdenes J, Totterman TH, Weigelt C. Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells. Cancer Immunol Immunother 2001 50 : 382 390